Key facts
- This page summarizes Charles N. Parker's Form 4 filing for Traws Pharma, Inc. (TRAW).
- 4 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 08 Apr 2026, 14:47.
Charles N. Parker - 12 Oct 2025 Form 4 Insider Report for Traws Pharma, Inc. (TRAW)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- TRAW
- Reported as of
- 12 Oct 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Apr 2026, 14:47:50 UTC
- Prior SEC filing
- 08 Apr 2026
- Next SEC filing
- 14 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles N. Parker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles N. Parker filed Form 4 for Traws Pharma, Inc. (TRAW) on 08 Apr 2026.
Change
- Previous filing in this sequence was filed on 08 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002125562
Primary reporting owner
Parker Charles Nolan
- Relationship
- Chief Financial Officer
- Address
- C/O TRAWS PHARMA, INC, 12 PENNS TRAIL, NEWTOWN
- Signature
- /s/ Charles N. Parker
- Signature date
- 08 Apr 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TRAW
transaction
Common Stock
Award
- Transaction value
- Shares
- +15,393
- Change %
- Price
- $0.000000*
- Shares after
- 15,393
- Date
- 12 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TRAW
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +32,406
- Change %
- Price
- $0.000000*
- Shares after
- 32,406
- Date
- 12 Oct 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 32,406
- Exercise price
- $3.01
- Footnotes
- F2
TRAW
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +61,571
- Change %
- Price
- $0.000000*
- Shares after
- 61,571
- Date
- 12 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 61,571
- Exercise price
- $2.33
- Footnotes
- F3
TRAW
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +104,544
- Change %
- Price
- $0.000000*
- Shares after
- 104,544
- Date
- 08 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 104,544
- Exercise price
- $1.60
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.
Footnote F2
Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Footnote F3
Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Footnote F4
Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.